Unity Biotechnology, Inc.
UBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $5 |
| % Growth | – | -100% | -95.1% | – |
| Cost of Goods Sold | $1 | $20 | $2 | $3 |
| Gross Profit | -$1 | -$20 | -$2 | $2 |
| % Margin | – | – | -823.7% | 39.8% |
| R&D Expenses | $13 | $21 | $37 | $38 |
| G&A Expenses | $15 | $19 | $21 | $23 |
| SG&A Expenses | $15 | $19 | $21 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$15 | -$35 | -$3 |
| Operating Expenses | $28 | $25 | $22 | $59 |
| Operating Income | -$31 | -$45 | -$58 | -$57 |
| % Margin | – | – | -24,394.9% | -1,184.5% |
| Other Income/Exp. Net | $5 | $5 | $13 | -$4 |
| Pre-Tax Income | -$26 | -$40 | -$44 | -$61 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$40 | -$44 | -$61 |
| % Margin | – | – | -18,842.8% | -1,269.3% |
| EPS | -1.54 | -2.7 | -4.68 | -10.9 |
| % Growth | 43% | 42.3% | 57.1% | – |
| EPS Diluted | -1.54 | -2.7 | -4.68 | -10.9 |
| Weighted Avg Shares Out | 17 | 15 | 9 | 6 |
| Weighted Avg Shares Out Dil | 17 | 15 | 9 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $4 | $3 |
| Depreciation & Amortization | $1 | $1 | $2 | $3 |
| EBITDA | -$25 | -$37 | -$39 | -$55 |
| % Margin | – | – | -16,411.4% | -1,142.7% |